
A NEW IDEA ON BIOTECH CYTK — GOOD TRIAL DATA — BUYOUT TARGET
By Nigam Arora CYTK is demonstrating good trial data in patients with obstructive hypertrophic cardiomyopathy. The data shows aficamten is superior to the current standard of care beta blockers. CYTK is a buyout target. To date, 205 Arora portfolio companies have been bought out. Producing a fortune for members who routinely invest in buyout targets. This record is better than firms that charge upwards of $50K per year. With The Arora Report, you get so much more. Zones For those following the Good Way, the Buy Now rating is *** (To see the locked content, please take a 30 day free






